Vanguard Group Inc. Raises Position in AdaptHealth Corp. (NASDAQ:AHCO)

Vanguard Group Inc. lifted its position in shares of AdaptHealth Corp. (NASDAQ:AHCO - Free Report) by 4.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,656,553 shares of the company's stock after buying an additional 355,005 shares during the period. Vanguard Group Inc. owned about 6.35% of AdaptHealth worth $78,775,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of AHCO. Commonwealth Equity Services LLC boosted its position in AdaptHealth by 1.8% during the third quarter. Commonwealth Equity Services LLC now owns 28,364 shares of the company's stock valued at $532,000 after purchasing an additional 491 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in AdaptHealth by 2.9% during the second quarter. The Manufacturers Life Insurance Company now owns 30,979 shares of the company's stock valued at $377,000 after purchasing an additional 887 shares during the last quarter. First Republic Investment Management Inc. boosted its position in AdaptHealth by 3.8% during the second quarter. First Republic Investment Management Inc. now owns 24,990 shares of the company's stock valued at $451,000 after purchasing an additional 924 shares during the last quarter. ProShare Advisors LLC boosted its position in AdaptHealth by 9.2% during the second quarter. ProShare Advisors LLC now owns 11,574 shares of the company's stock valued at $141,000 after purchasing an additional 978 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in AdaptHealth by 2.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 37,652 shares of the company's stock valued at $469,000 after purchasing an additional 984 shares during the last quarter. 82.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at AdaptHealth

In other AdaptHealth news, major shareholder James E. Flynn sold 182,607 shares of AdaptHealth stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $11.02, for a total transaction of $2,012,329.14. Following the completion of the transaction, the insider now owns 11,643,769 shares in the company, valued at approximately $128,314,334.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other AdaptHealth news, major shareholder James E. Flynn sold 182,607 shares of AdaptHealth stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $11.02, for a total transaction of $2,012,329.14. Following the completion of the transaction, the insider now owns 11,643,769 shares in the company, valued at approximately $128,314,334.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder James E. Flynn sold 52,487 shares of the business's stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $10.93, for a total value of $573,682.91. Following the completion of the transaction, the insider now owns 11,826,376 shares in the company, valued at approximately $129,262,289.68. The disclosure for this sale can be found here. Company insiders own 13.60% of the company's stock.

Wall Street Analysts Forecast Growth

AHCO has been the topic of several research analyst reports. UBS Group upped their price objective on AdaptHealth from $9.00 to $13.00 and gave the company a "buy" rating in a research note on Wednesday, February 28th. Jefferies Financial Group lowered AdaptHealth from a "buy" rating to a "hold" rating and lowered their target price for the stock from $14.50 to $8.00 in a research note on Monday, January 8th. Truist Financial increased their target price on AdaptHealth from $11.00 to $13.00 and gave the stock a "buy" rating in a research note on Wednesday, February 28th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $13.00 target price on shares of AdaptHealth in a research note on Monday, March 4th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $12.10.

AdaptHealth Stock Up 0.3 %

AdaptHealth stock traded up $0.03 during midday trading on Friday, reaching $10.47. The stock had a trading volume of 1,049,006 shares, compared to its average volume of 905,211. AdaptHealth Corp. has a 12 month low of $6.37 and a 12 month high of $15.37. The company has a market capitalization of $1.39 billion, a P/E ratio of -1.97, a PEG ratio of 0.69 and a beta of 1.02. The company has a fifty day moving average price of $9.30 and a two-hundred day moving average price of $8.30. The company has a current ratio of 1.21, a quick ratio of 1.00 and a debt-to-equity ratio of 1.44.

AdaptHealth (NASDAQ:AHCO - Get Free Report) last issued its earnings results on Tuesday, February 27th. The company reported $0.64 EPS for the quarter, beating analysts' consensus estimates of $0.20 by $0.44. AdaptHealth had a positive return on equity of 8.84% and a negative net margin of 21.21%. The business had revenue of $858.23 million during the quarter, compared to analyst estimates of $825.94 million. As a group, equities analysts expect that AdaptHealth Corp. will post 0.88 EPS for the current fiscal year.

AdaptHealth Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.